PCL Polycaprolactone Microspheres | Long-Acting Flexible Regenerative Base Material
Technical Specifications
Particle Size (D50): 25–50μm
Purity: ≥98%
Endotoxin: ＜0.1 EU/mg
Degradation Period: 12–24 months
Product Introduction
Polycaprolactone (PCL) is a medical-grade degradable regenerative raw material featuring low irritation, ultra-long service life and superior biocompatibility. As a semi-crystalline aliphatic polyester, it has been validated through long-term global clinical application and serves as a benchmark base material for long-term soft tissue regeneration, sustained-release biological preparations and tissue engineering.
Compared with PLA-based polyester raw materials, PCL degrades mildly and steadily without local accumulation of acidic metabolites, resulting in extremely low risk of inflammatory irritation and better cellular compatibility as well as soft tissue adhesion. Relying on its ultra-long degradation cycle, stable 3D supporting framework and continuous collagen-inducing capacity, the material is developed for long-term deep soft tissue regeneration, persistent contour maintenance and aged tissue repair. It acts as a core raw material for high-end long-acting regenerative medical devices, compliant medical compound substrates and tissue engineering R&D. It can be compounded with recombinant Type I/III collagen, silk fibroin and other bioactive proteins, as well as hyaluronic acid, to form a composite raw material solution of Regenerative Microspheres + Bioactive Proteins, supporting project initiation and industrial mass production of long-acting regenerative medical devices.
Mechanism of Action
After implantation into soft tissue, high-purity PCL microspheres undergo steady, long-cycle mild hydrolytic degradation with controllable degradation rate and mild, low-irritation metabolites, fundamentally reducing adverse reactions such as erythema, edema, induration and inflammatory nodules of finished preparations.
The microsphere framework can long-term activate the physiological activity of fibroblasts, guiding layered and ordered regeneration of autologous collagen fibers and elastic fibers, so as to precisely improve aging defects including deep facial depressions, severe soft tissue volume loss, stubborn static wrinkles and sagging facial contours.
The material delivers three-phase efficacy: short-term soothing and soft tissue conditioning, medium-to-long-term three-dimensional collagen remodeling and regeneration, as well as long-term contour shaping and stabilization. The regenerative effect advances gradually with stable and long-lasting efficacy, realizing synchronous optimization of facial contour and skin texture, and the shaping texture is naturally consistent with native tissue morphology.
Core Product Advantages
Ultra-Low Inflammatory Irritation, Excellent Medical Safety
No acidic accumulation during degradation leads to an extremely low incidence of inflammation and outstanding cellular biocompatibility. It is applicable to multiple scenarios including vulnerable soft tissue repair, superficial soft tissue care and deep contour shaping, with better comprehensive safety than conventional polyester regenerative microsphere raw materials.
Ultra-Long-Term Regeneration, Outstanding Contour Retention Cycle
With industry-leading long-lasting degradation characteristics, its collagen induction and regeneration effects can be released continuously to achieve long-term contour fixation and refined skin repair, perfectly matching the product positioning of high-end long-acting anti-aging and steady-state regenerative medical devices.
Full-Dimensional Customization of Physicochemical Parameters
Particle size, molecular weight, degradation cycle and microsphere morphology can be customized on demand. We can produce multi-specification raw materials for short-term repair, medium-term revitalization and long-term contour fixation. A single base raw material can support customers to deploy multiple differentiated product lines.
Superior Compounding Compatibility to Cut R&D Trial-and-Error Costs
It enjoys excellent compatibility with hyaluronic acid, botanical polysaccharides, various biological regenerative substrates and active protein systems. The compound system achieves uniform dispersion without agglomeration or delamination, effectively saving customers’ time and material costs for formula debugging, new product sampling and formula iteration.
Implant-Grade Medical Quality Control for Medical Device Registration Compliance
Manufactured via closed polymerization process with high-purity medical monomers to realize ultra-low impurity residues and high consistency among production batches. The whole production process complies with the quality control standards for implantable medical raw materials, and all indicators meet the access requirements for Class II and Class III implantable medical device raw materials, guaranteeing both commercial compliance and raw material stability.
Target Customers & Application Scope
Overseas medical device manufacturers, leading domestic medical aesthetic raw material supply chain groups, biomedical research institutes, biomaterial research laboratories
Commercial Application Scenarios
Mass Production Support for Medical Device Manufacturers
Served as core raw material for the industrial production of PCL+HA long-acting composite regenerative substrates, steady anti-aging contouring materials and deep soft tissue repair implantable devices, supporting the manufacturing of finished long-acting regenerative medical devices.
Compound Cooperation with Large-Scale Raw Material Groups
Supply bulk industrial-grade PCL microspheres. Partners can conduct secondary compounding with bioactive proteins and hydrogel matrices to develop differentiated composite regenerative raw materials for distribution at home and abroad.
R&D Sample Cooperation for Scientific Research Institutions
Provide standard test samples and customized modified samples for biomaterial research projects, pre-development of long-acting regenerative medical devices, animal efficacy verification, as well as pharmacology and toxicology tests in the early stage of medical device registration.
Compliance Disclaimer
Our company focuses on the R&D and bulk sales of biomedical raw materials. We do not supply products to medical aesthetic clinics, beauty salons or individual end consumers, nor do we produce, subpackage or sell finished medical aesthetic devices and skincare products. Customers shall independently complete formula development, preparation processing, domestic & overseas medical device registration certification and other commercial procedures. Finished products can only be launched into market after obtaining full compliance approval. The content on this page only objectively demonstrates the physicochemical properties and application directions of raw materials, and shall not be regarded as efficacy commitment for finished medical devices, clinical operation guidance or commercial efficacy endorsement.